肾病综合征患者血浆可溶性内皮细胞蛋白C受体水平变化及临床意义

Clinical Significance of Soluble Endothelial Cell Protein C in Patients with Nephritic Syndrome

目的 检测肾病综合征（nephrotic syndrome,NS）患者血浆中可溶性内皮细胞蛋白C受体（soluble endothelialcell protein C receptor,sEPCR）的水平,初步探讨其临床意义.方法 采用酶联免疫双抗夹心法对65例NS及48名正常对照组血浆的sEPCR进行检测,同步检测各组血浆凝血酶时间（PT）、活化部分凝血酶时间（APTT）水平.结果 NS组患者血浆sEPCR（357.0±156.80ng/mL）较正常对照组（155.68±32.01ng/mL）显著升高,差异有统计学意义（P〈0.05）.在NS组中,膜性肾病组血浆sEPCR水平比微小病变组及系膜增生组高,差异有统计学意义（P〈0.05）.PT、APTT在各组的表达差异无统计学意义（P〉0.05）.结论 sEPCR可能参与NS患者血栓形成过程,是高凝状态的预测指标之一.

Objective To investigate soluble EPCR（sEPCR） levels in patients with nephrotic syndrome（NS）. Methods Sixty-five NS patients were recruited and divided into the minimal change disease（MCD）,membranous nephropathy（MN）,mesangial proliferative glomerulonephritis（MsPGN）.Plasma sEPCR, PT, APTT levels were measured in all groups.Moreover,48 healthy subjects were evaluated regarding sEPCR,APTT, PT. Results There was no difference in APTT, PT between the groups.In the NS subjects,sEPCR was found to be 357.0 ±156.8ng/ mL at baseline.In the healthy subjects, sEPCR was found to be 155.68 ± 32.01ng/mL at baseline,which was lower than in NS groups.Moreover, sEPCR in group MN was significantly increased than in group MCD and MsPGN. Conclusions We showed that the recently proposed endothelial damage and thrombosis biomarkers,sEPC1L are elevated in NS patients,especially in MN patients.